Clinical trial of COVID-2019 and quadrivalent seasonal influenza combined vaccine in USA
Latest Information Update: 24 Jun 2021
At a glance
- Drugs COVID-2019-quadrivalent seasonal influenza combined vaccine-Medigen Vaccine Biologics/Vaxess Technologies (Primary)
- Indications COVID 2019 infections; Influenza virus infections
- Focus Adverse reactions; First in man; Proof of concept
- 22 Apr 2021 According to a Vaxess Technologies media release, the company will file IND within a year and trial is expected to start in the first half of 2022.
- 22 Apr 2021 According to a Vaxess Technologies media release, the company was awarded a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID grant number SB1AI164584), a part of the U.S. National Institutes of Health (NIH).
- 22 Apr 2021 According to a Vaxess Technologies media release, the CRP grant will be used to advance the commercialization of the MIMIX technology via CMC activities including design and quality control systems, clinical lot manufacturing, and continued engagement with regulatory stakeholders in preparation for a Phase I clinical trial.